Singh Gurjot, Trehan Shubam, Goswami Kanishka, Singh Adarshpreet, Puri Piyush
Internal Medicine, Maharaj Sawan Singh Charitable Hospital, Beas, IND.
Medicine, Punjab Institute of Medical Sciences, Jalandhar, IND.
Cureus. 2024 Jul 14;16(7):e64512. doi: 10.7759/cureus.64512. eCollection 2024 Jul.
Catamenial asthma, marked by cyclical exacerbations of symptoms linked to the menstrual cycle, poses distinctive diagnostic and therapeutic challenges. This report discusses a 34-year-old woman who experienced significant asthma flare-ups 3-5 days before menstruation, as confirmed by spirometry (forced expiratory volume in one second (FEV1) dropped from 2.5 to 1.75 liters). Despite adhering to standard asthma treatments, her symptoms remained poorly controlled during these periods. A comprehensive management plan encompassing inhaled corticosteroids, short-acting beta-agonists, montelukast, and oral contraceptives, along with lifestyle modifications and patient education, led to a significant improvement in FEV1 and reduced symptom severity. This case underscores the need for personalized treatment strategies that take hormonal influences into account, suggesting that integrating hormonal therapies with conventional asthma management can yield significant benefits.
月经性哮喘的特征是症状与月经周期相关的周期性加重，带来了独特的诊断和治疗挑战。本报告讨论了一名34岁女性，她在月经前3至5天出现严重哮喘发作，肺功能测定（一秒用力呼气量（FEV1）从2.5升降至1.75升）证实了这一点。尽管坚持标准哮喘治疗，但在这些时期她的症状仍控制不佳。一个综合管理计划，包括吸入性糖皮质激素、短效β受体激动剂、孟鲁司特和口服避孕药，以及生活方式改变和患者教育，使FEV1显著改善，症状严重程度降低。该病例强调了需要考虑激素影响的个性化治疗策略，表明将激素疗法与传统哮喘管理相结合可产生显著益处。
